This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer
by Zacks Equity Research
Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA
by Zacks Equity Research
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
Company News For Sep 26, 2018
by Zacks Equity Research
Companies in the news are: FDS, SONC, AZN and EVHC
AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer
by Zacks Equity Research
AstraZeneca's (AZN) PD-L1 inhibitor Imfinzi gets approval in EU for an early-stage lung cancer indication.
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.
NVS vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. AZN: Which Stock Is the Better Value Option?
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
by Zacks Equity Research
In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
by Zacks Equity Research
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
by Zacks Equity Research
AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
by Indrajit Bandyopadhyay
Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.
Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
by Ekta Bagri
Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.
AstraZeneca Up This Year So Far on Favorable Pipeline Updates
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
AstraZeneca's Lupus Drug Misses Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis
by Zacks Equity Research
Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.